Strategies to Overcome Hurdles in Cancer Immunotherapy
Biomaterials Research · 2024-01 · 28
DOI: 10.34133/bmr.0080 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomaterials Research, online erschienen am 19.09.2024. Verfasst von Jihyun Kim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute for Pharmaceutical Sciences, College of Pharmacy, College of Pharmacy,Seoul National University, Seoul 08826, Republic of Korea. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 134 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Despite marked advancements in cancer immunotherapy over the past few decades, there remains an urgent need to develop more effective treatments in humans. This review explores strategies to overcome hurdles in cancer immunotherapy, leveraging innovative technologies including multi-specific antibodies, chimeric antigen receptor (CAR) T cells, myeloid cells, cancer-associated fibroblasts, artificial intelligence (AI)-predicted neoantigens, autologous vaccines, and mRNA vaccines. These approaches aim to address the diverse facets and interactions of tumors’ immune evasion mechanisms. Specifically, multi-specific antibodies and CAR T cells enhance interactions with tumor cells, bolstering immune responses to facilitate tumor infiltration and destruction. Modulation of myeloid cells and cancer-associated fibroblasts targets the tumor’s immunosuppressive microenvironment, enhancing immunotherapy efficacy. AI-predicted neoantigens swiftly and accurately identify antigen targets, which can facilitate the development of personalized anticancer vaccines. Additionally, autologous and mRNA vaccines activate individuals’ immune systems, fostering sustained immune responses against cancer neoantigens as therapeutic vaccines. Collectively, these strategies are expected to enhance efficacy of cancer immunotherapy, opening new horizons in anticancer treatment.
Autor:innen und Institutionen
- Research Institute for Pharmaceutical Sciences, College of Pharmacy, College of Pharmacy,Seoul National University, Seoul 08826, Republic of Korea.
- Interdisciplinary Program for Bioengineering, Seoul National University, Seoul 08826, Republic of Korea.
- Department of Anatomy and Cell Biology, Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.
- Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 08826, Republic of Korea.
- Arontier Co., Seoul 06735, Republic of Korea.
- School of Chemical and Biological Engineering, Seoul National University, Seoul 08826, Republic of Korea.
ORCID-Profile: Yeonseok Chung
Förderung
- National Research Foundation of Korea
Zitieren
APA
Kim, J., Lee, B. J., Moon, S., Lee, H., Lee, J., Kim, B. S., Jung, K., Seo, H., & Chung, Y. (2024). Strategies to Overcome Hurdles in Cancer Immunotherapy. Biomaterials Research, 28. https://doi.org/10.34133/bmr.0080
Vancouver
Kim J, Lee BJ, Moon S, Lee H, Lee J, Kim BS, et al. Strategies to Overcome Hurdles in Cancer Immunotherapy. Biomaterials Research. 2024;28. doi:10.34133/bmr.0080
BibTeX
@article{Kim2024,
author = {Kim, Jihyun and Lee, Byung Joon and Moon, Sehoon and Lee, Hojeong and Lee, Juyong and Kim, Byung-Soo and Jung, Keehoon and Seo, Hyungseok and Chung, Yeonseok},
title = {Strategies to Overcome Hurdles in Cancer Immunotherapy},
journal = {Biomaterials Research},
year = {2024},
volume = {28},
doi = {10.34133/bmr.0080}
}
EUVIMED